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Innovations
Basilea Pharmaceutica AG
Mining a Rich Inheritance
the assets we were born with, our may have broader efficacy than
other retinoids. It is hypothesizedcurrent focus and core competency
that BAL 4079 may exert its effectis in the treatment of infectious dis-
Given that Basilea only opened its
doors in October 2000, you may not
yet be familiar with their name and
their mission to develop novel on eczema by decreasing Th1 celleases and dermatological dis-
anti-infective and dermatological activity and inhibiting the release ofeases.” “Our two most advanced
therapies. But this Basel, Switzer- cytokines. The published results ofproducts now are in the dermatology
land-based, Research and Develop- a 38-person open-label pilot trial forarea,” adds Discovery Program
ment-focused company has a chronic hand eczema indicated thatHead Malcolm Page, PhD, himself a
powerhouse of a parent in F. Hoff- 34 participants had a response toten year Roche veteran. BAL 4079,
mann-La Roche Ltd. According to the medication, ranging from goodor alitretinoin, is an oral vitamin A
Basilea’s CEO, Dr. Gu¨nther Kinast, to very good, with only two patientsderivative developed for the treat-
the company’s objective is to join exhibiting no response. The side ef-ment of chronic hand eczema, which
the “Champions League” of the bio- fects were mild, with 29% of partici-is now in phase II trials. Man de-
tech and pharmaceutical world. For- pants experiencing cheilitis (drynessscribes this drug as the lead agent,
tunately, the company has a jump and cracking) and 11% each havingby far, of all compounds in devel-
start on this goal: in only two years it headache or flush. Other Th1-cell-opment.
has progressed to produce a steady mediated diseases like multiple
flow of innovative compounds and sclerosis, lupus, Crohn’s Disease,
already has two compounds in and rheumatoid arthritis may also be
“Because of the assetsphase II testing. considered for clinical investigation,
but Man is quick to add that BALIn 1999, when Roche made its we were born with, our
strategic decision to refocus its own 4079 has not been tested for effec-current focus and core
R&D activities away from anti-infec- tiveness in these, or other, diseases.
competency is in thetives and dermatologicals, rather Basilea is targeting a patient pop-
ulation with chronic hand eczemathan scrap or license away all the treatment of infectious
technology that its scientists had ac- who do not respond to conventionaldiseases and derma-
crued to its competitors, it decided topical therapy such as steroids and
tological diseases.”to create a new, distinct company emollients. “There is no good alter-
native for that particular patient,”(Basilea), to which it assigned perti- –Anthony Man, MD,
nent drug candidates and all rele- says Man. Should BAL 4079 pass itsBasilea Chief Develop-
vant intellectual property. Conse- clinical and regulatory hurdles, it will
ment Officerquently, Basilea’s 110 employees join the ranks of other retinoids in-
have one goal: to develop and dis- cluding tretinoin (Retin-A), isotreti-
cover new antimicrobial and derma- noin (Accutane), and actitretin (Sori-
“BAL 4079 is a natural compound,tological therapeutics. Aside from atane). The current phase II study is
and it’s important to realize retinoidsthe management team, almost ev- a randomized, double-blind, pla-
are a very heterogeneous group,”eryone at Basilea is involved in re- cebo-controlled 300-person trial
explains Man. Further, in the fieldsearch and clinical development comparing several doses. “We should
of dermatology there is a record ofprojects that are driven by mining have the results out by the end of
retinoid efficacy in various diseasethe assets inherited from Roche. It 2002,” says Man.
types, including acne, psoriasis, andis noteworthy that although Basilea The company’s other promising
eczema. “But it’s not possible tois an independent company, Roche dermatology therapeutic is BAL
predict preclinically which diseasestill holds 49% minority ownership 2299, a vitamin D derivative in early
may be helped by which retinoid.”and retains an opt-in right at the end phase II tests for psoriasis. In this
He adds it is equally difficult to ex-of phase II development on seven case, the clinical trials have ad-
trapolate which drug will be mostof the compounds currently in the vanced further, “We’ve identified an
effective as an oral systemic drugBasilea pipeline. appropriate dose for the BAL 2299
or as a topical agent. “The receptorDermatology Compounds phase II study and we’re in explor-
subtype to which a retinoid bindsin the Lead atory clinical testing now with that
likely determines, to some extent,When the company was formed, drug,” says Man. For mild psoriasis,
the diseases for which it may be ef-most of the R&D staff came from a number of topical psoriasis medi-
fective in treating,” Man continues.Roche. “So did five development cations are available including vita-
“BAL 4079 binds to the both the RARcompounds that we’re pursuing min D3 derivatives. At the severe end
and RXR families of retinoid recep-now,” says Chief Development Offi- of the spectrum for the disease, ar-
thritis and other complications re-cer Anthony Man, MD. “Because of tors.” This suggests that this agent
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quire more extreme and aggressive nia” according to Man, “and strepto- hundreds of thousands of synthetic
compounds for screening in addi-treatment with immunosuppres- cocci infections are also involved in
skin and soft tissue infections insants or biological agents such as tion to the natural product library,”
explains Man.monoclonal antibodies. “We’re posi- both the hospital and community.”
While staphlycocci and streptococcitioning BAL 2299 somewhere in be- In partnership with its parallel
chemistry group, and also with atween the gap between the topical are part of the normal indigenous
bacterial flora, under certain condi-applications and these ‘high-tech’ head start from Roche, Basilea is de-
veloping new chemistry automationtherapies. We are hoping to have a tions they will overgrow and cause
disease. “They are notoriously resis-psoriasis compound that would sat- that is more flexible than current
conventional combinatorial chemis-isfy the needs of patients for whom tant to most antibiotics,” says Man,
“but vancomycin is effective in sometopical treatments are either ineffec- try. “We do targeted chemistry using
information from screening our com-tive or inconvenient, but for whom cases of resistant staph infection.”
However, with the increasing preva-more high-tech solutions often in- pound libraries and our extensive
knowledge of the crystal structuresvolving immunosuppression are a lence of antibiotic-resistant strains
of bacteria and the resultant increas-bit too heavy handed.” of new targets to design new li-
gands, and then make small focusedBroad-Spectrum Antibiotic ing use of vancomycin, vancomycin
resistance has developed in certainin Its Sights libraries rather than the large, homo-
geneous sets that have been theIn addition to the dermatological organisms, particularly in Europe
and Japan, but to some extent intherapies, Basilea has a broad- fashion with combinatorial chemis-
try,” explains Page.spectrum IV cephalosporin pro- North America too. “However, we do
not believe that BAL 5788 shoulddrug, BAL 5788, just about to enter While Basilea will have plenty to
do with its treasure from Roche forinto phase II for dose confirmation. be limited to glycopeptide-resistant
gram-positive bacteria, because itsExcitingly, this drug has activity the foreseeable future, they are ac-
tively interested in collaborationsagainst both gram-positive and gram- in vitro profile also extends to gram-
negative organisms,” says Man. Nei-negative bacteria. “Clinically, some with other companies for licensing-
in opportunities. While no suchof the most worrisome pathogens ther vancomycin nor some of the
newer drugs such as linezolide orare the gram-positive cocci—staph- agreements have been announced
publicly, talks are in the works withlycocci, enterococci, streptococci— quinupristin/dalfopristin have ac-
tivity against gram-negative or-which are causing big problems at several prospective partners. “In
comparison with typical start-upthe moment,” says Page, who was ganisms.
Antifungals Complete the Coreon the drug’s development team at companies, we have a big develop-
ment product portfolio,” says Man.Roche. He explains, “One key ad- Program
In the antifungal arena, Basilea is de-vantage of the BAL 5788 drug is that “Though we’re always interested in
new opportunities, we certainly haveit combines well-established fea- veloping BAL 8557, a water-soluble
azole, which is being produced bothtures of a -lactam antibiotic agent enough going on in-house to keep
us busy.”with very good activity against meth- as an oral and IV therapy. “This gives
the clinician a choice for applica-icillin-resistant Staphylococcus au-
Chemistry & Biology invites yourreus, or MRSA.” MRSA is a major tions,” says Page, “depending on
comments on this topic. Pleaseproblem in many hospitals through- the type and site of infection.” BAL
write to the editors at chembiol@out the world, and many facilities are 8557 will primarily be targeted for
cell.com.now resorting to their last line of de- treatment of serious invasive sys-
temic fungal infections. “You canfense against it, principally with van- Alice A. McCarthy is a freelance science
comycin. “There is a severe short- start patients who are seriously ill on writer based in Gloucester, MA (alice@
alicemccarthy.com).age of drugs available for effective the IV form, then switch to the oral
once the infection is better con-treatment of MRSA infections,” ac-
cording to Page. trolled,” adds Man. BAL 8557 is just
about to enter phase I testing. TheBAL 5788 has also exhibited activ-
ity against penicillin-resistant Strep- other antifungal effort is a preclinical
project focused on inhibition of glu-tococcus pneumonia, viridans strep-
tococci, and coagulase-negative can synthase. “We have a number of
molecules from this field,” he says,staphlycocci such as Staphylococ-
cus epidermidis. “Staphylococcus is “and we’ll probably decide by the
end of the year how to proceed withthe most common cause of infection
in humans,” says Man. “You’ll find this group of compounds.”
Natural Products Library andthe infections both in the out-patient
community and hospital settings.” It Chemistry Automation
When Basilea was formed, it also in-is also commonly involved in wound
(skin and soft tissue) infections. herited a “natural products strain
collection,” a microbe library ofStreptococcal infections are com-
monly acquired as lower respiratory 120,000 organisms, each with the
potential or proven ability to synthe-infections. “In fact, Streptococcus
pneumonia is the lead cause of com- size antibiotics or other therapeutic
agents. “We have access to severalmunity-acquired bacterial pneumo-
